Purple Biotech Plans to Strengthen IM1240 Research in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy PPBT?
"In 2025, we focused on the CAPTN-3 platform and the value it can generate for patients and shareholders, naming a second tri-specific antibody from the platform, IM1305, and strengthening the preclinical data package for the first tri-specific antibody, IM1240. In addition, the capital we raised in 2025 is expected to provide runway into 2027, covering preparations for IM1240 Phase 1 study initiation," said Gil Efron, Purple Biotech CEO. "During the past year, we made efforts to partner both CM24 and NT219 and, as previously reported, we will not be able to continue developing these assets until we obtain a strategic investment or a partner. We are excited by the increasing interest in assets similar to CAPTN-3. With a cash position of $9.5 million at the end of 2025, and with data demonstrating that tri-specific antibodies from the CAPTN-3 platform deliver in vivo efficacy, a favorable therapeutic window, and scalable manufacturability, we look forward to sharing additional data and advancing the program over the course of this year," Gil concluded.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PPBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PPBT
Wall Street analysts forecast PPBT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.725
Low
34.00
Averages
34.00
High
34.00
Current: 3.725
Low
34.00
Averages
34.00
High
34.00
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
Purple Biotech CEO Gil Efron to Step Down in August 2026
- Executive Transition: Purple Biotech announced that CEO Gil Efron will step down in August 2026, marking the end of his eight-year tenure in senior leadership roles, including Chief Financial Officer and CEO, indicating a significant shift in the company's leadership structure.
- Leadership Experience: Efron has served as CEO since 2022, during which the company underwent several strategic adjustments; while specific performance metrics are not disclosed, his decisions will have lasting implications for the company's future trajectory.
- Market Reaction: This announcement may raise investor concerns regarding the company's future direction, particularly during the leadership transition, which could impact stock prices and market confidence, necessitating close monitoring of subsequent leadership selection.
- Strategic Planning: Purple Biotech must establish a clear succession plan following Efron's departure to ensure continuity and stability in its strategic initiatives, mitigating potential disruptions to business operations due to leadership changes.
See More
Purple Biotech CEO Steps Down Due to Health Reasons
- Executive Change: Purple Biotech Ltd.'s CEO Gil Efron will step down in August due to health considerations, although he will remain with the company to lead corporate development, demonstrating his ongoing commitment to the firm.
- Successor Search: The company has initiated a formal search process for a new CEO, which could significantly impact the strategic direction and future growth of the company.
- Stock Price Reaction: Prior to the announcement of Efron's resignation, PPBT shares closed at $3.84 on Nasdaq, down 4.24%, indicating market sensitivity to executive changes.
- Health Considerations: Efron stated that due to health reasons, he believes it is the right time to transition from the CEO role, which may affect investor confidence in the company's future.
See More
PURPLE BIOTECH LTD ANNOUNCES GIL EFRON'S RESIGNATION AS CEO, EFFECTIVE AUGUST 2026
- Company Announcement: Purple Biotech Ltd. has announced the resignation of Gil Efron as CEO, effective August 20, 2026.
- Leadership Transition: The company is likely to undergo a leadership transition as it seeks a new CEO to guide its future direction.
See More
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
Purple Biotech CEO Gil Efron to Step Down in August 2026
- Executive Transition: Purple Biotech announced that CEO Gil Efron will step down in August 2026, marking the end of his eight-year tenure in senior leadership roles, including Chief Financial Officer and CEO, indicating a significant shift in the company's leadership structure.
- Leadership Experience: Efron has served as CEO since 2022, during which the company underwent several strategic adjustments; while specific performance metrics are not disclosed, his decisions will have lasting implications for the company's future trajectory.
- Market Reaction: This announcement may raise investor concerns regarding the company's future direction, particularly during the leadership transition, which could impact stock prices and market confidence, necessitating close monitoring of subsequent leadership selection.
- Strategic Planning: Purple Biotech must establish a clear succession plan following Efron's departure to ensure continuity and stability in its strategic initiatives, mitigating potential disruptions to business operations due to leadership changes.
See More
Purple Biotech CEO Steps Down Due to Health Reasons
- Executive Change: Purple Biotech Ltd.'s CEO Gil Efron will step down in August due to health considerations, although he will remain with the company to lead corporate development, demonstrating his ongoing commitment to the firm.
- Successor Search: The company has initiated a formal search process for a new CEO, which could significantly impact the strategic direction and future growth of the company.
- Stock Price Reaction: Prior to the announcement of Efron's resignation, PPBT shares closed at $3.84 on Nasdaq, down 4.24%, indicating market sensitivity to executive changes.
- Health Considerations: Efron stated that due to health reasons, he believes it is the right time to transition from the CEO role, which may affect investor confidence in the company's future.
See More
PURPLE BIOTECH LTD ANNOUNCES GIL EFRON'S RESIGNATION AS CEO, EFFECTIVE AUGUST 2026
- Company Announcement: Purple Biotech Ltd. has announced the resignation of Gil Efron as CEO, effective August 20, 2026.
- Leadership Transition: The company is likely to undergo a leadership transition as it seeks a new CEO to guide its future direction.
See More
